Skip to main content

Table 3 Characteristics of included studies (Part 3). Additional data

From: Role of ursodeoxycholic acid in neonatal indirect hyperbilirubinemia: a systematic review and meta-analysis of randomized controlled trials

  

UDCA supplementation group (UDCA + phototherapy)

Control group (phototherapy only)

  

No

Author

Phototherapy duration (hours)

Last mean bilirubin reported (mg/dL)

Phototherapy duration (hours)

Last mean bilirubin reported (mg/dL)

Type of phototherapy lamp

Thresholds for phototherapy

1

Akefi [25]

34.6 (16.3)

35.7 (18.2)

Simple phototherapy

Standard curve

2

El-Gendy [26]

65.2 (12.8)

9.42 (0.82) (96 h)

82.5 (19.4)

10.5 (1.35) (96 h)

Single PT

3

Gharehbaghi [27]

29.47 (16.8)

4.75 (1.07) (discharge)*

45.97 (18.01)

7.88 (2.11) (discharge)*

LED

AAP guidelines, termination: decrease in TSB < 50% exchange threshold

or TSB < 10 mg/dl

4

Hassan [28]

23.2 (5.6)

7.6 (0.9) (36 h)

41.1 (7.2)

9.1 (0.8) (48 h)

LED

5

Honar [21]

15.5 (6)

9.8 (0.2) (48 h)

44.6 (13.3)

10.1 (1.1) (48 h)

Daylight fluorescent

Until TSB < 10 mg/dL

6

Jafari [29]

14.61 (2.29) (16 h)

12.58 (2.25) (36 h)

Until TSB normalised

7

Meena [30]

9.48 (0.68) (48 h)

9.99 (0.66) (48 h)

LED

Until TSB < 10 mg/dL

8

Shahramian [31]

Daylight fluorescent

Until TSB < 10 mg/dL

  1. TSB Total serum bilirubin, PT Phototherapy
  2. *Reported as indirect bilirubin in mg/dL